Additionally, PARP-1 overexpression inhibits the recruitment of death-inducing signaling complex in pancreatic cancer cells, offering the ability to resist TNF-related apoptosis-inducing ligand (TRAIL) therapy [13]. This evidence concerns the gene PARP1 and pancreatic neoplasm.